2024
Plasma proteomics of acute tubular injury
Schmidt I, Surapaneni A, Zhao R, Upadhyay D, Yeo W, Schlosser P, Huynh C, Srivastava A, Palsson R, Kim T, Stillman I, Barwinska D, Barasch J, Eadon M, El-Achkar T, Henderson J, Moledina D, Rosas S, Claudel S, Verma A, Wen Y, Lindenmayer M, Huber T, Parikh S, Shapiro J, Rovin B, Stanaway I, Sathe N, Bhatraju P, Coresh J, Rhee E, Grams M, Waikar S. Plasma proteomics of acute tubular injury. Nature Communications 2024, 15: 7368. PMID: 39191768, PMCID: PMC11349760, DOI: 10.1038/s41467-024-51304-x.Peer-Reviewed Original ResearchConceptsAcute tubular injuryAcute kidney injuryPathway analysisOrganelle stress responsesSingle-cell RNA sequencingKidney Precision Medicine ProjectKidney diseaseSOMAscan proteomics platformProgression to kidney failureRNA sequencingBiological pathwaysGene expressionStress responseNon-invasive biomarkersProteomics platformMannose receptor 1Kidney injuryTubular injuryImmune regulationReceptor 1Macrophage mannose receptor 1Host responseBiomarker proteinsPrecision Medicine ProjectKidney failure
2023
The ASSESS-AKI Study found urinary epidermal growth factor is associated with reduced risk of major adverse kidney events
Menez S, Wen Y, Xu L, Moledina D, Thiessen-Philbrook H, Hu D, Obeid W, Bhatraju P, Ikizler T, Siew E, Chinchilli V, Garg A, Go A, Liu K, Kaufman J, Kimmel P, Himmelfarb J, Coca S, Cantley L, Parikh C. The ASSESS-AKI Study found urinary epidermal growth factor is associated with reduced risk of major adverse kidney events. Kidney International 2023, 104: 1194-1205. PMID: 37652206, PMCID: PMC10840723, DOI: 10.1016/j.kint.2023.08.007.Peer-Reviewed Original ResearchConceptsMajor adverse kidney eventsUEGF/CrUrinary epidermal growth factorAdverse kidney eventsChronic kidney diseaseEpidermal growth factorKidney eventsKidney failureEGF expressionUrinary EGF/CrAcute Kidney Injury studyGrowth factorIschemia-reperfusion injuryProportional hazards regressionTubular healthKidney atrophyObservational cohortHospitalized participantsTubular functionClinical findingsHazards regressionKidney diseaseClinical variablesProgressive atrophyUrinary EGF
2020
Inhibiting calpain 1 and 2 in cyclin G associated kinase–knockout mice mitigates podocyte injury
Tian X, Inoue K, Zhang Y, Wang Y, Sperati CJ, Pedigo CE, Zhao T, Yan M, Groener M, Moledina DG, Ebenezer K, Li W, Zhang Z, Liebermann D, Greene L, Greer P, Parikh CR, Ishibe S. Inhibiting calpain 1 and 2 in cyclin G associated kinase–knockout mice mitigates podocyte injury. JCI Insight 2020, 5: e142740. PMID: 33208557, PMCID: PMC7710277, DOI: 10.1172/jci.insight.142740.Peer-Reviewed Original ResearchConceptsCalpain-1Chronic kidney diseaseDegree of proteinuriaCalpain inhibitor IIIGlomeruli of patientsProgressive proteinuriaCalpain protease activityGlobal glomerulosclerosisGlomerular injuryKidney functionKidney diseaseKidney failureCalcium dysregulationPodocyte injuryPodocyte-specific deletionPodocyte damageG associated kinaseProtective roleCalpain activationProteinuriaGlomerulosclerosisMiceReduced expressionStriking increaseInjury
2016
PPIs and kidney disease: from AIN to CKD
Moledina DG, Perazella MA. PPIs and kidney disease: from AIN to CKD. Journal Of Nephrology 2016, 29: 611-616. PMID: 27072818, DOI: 10.1007/s40620-016-0309-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute interstitial nephritisProton pump inhibitorsChronic kidney diseaseKidney diseaseDrug-induced acute interstitial nephritisExcellent overall safety profileHigher CKD riskSystemic allergic manifestationsAcute kidney injuryAdverse renal eventsGlomerular filtration rateOverall safety profilePopulation-based studyMillions of patientsAIN diagnosisRenal eventsCKD riskKidney injuryAllergic manifestationsInterstitial nephritisMedian timeSafety profileDrug initiationKidney failurePump inhibitors